Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2007-03-06
2007-03-06
Crouch, Deborah (Department: 1632)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S007100, C435S325000
Reexamination Certificate
active
09961381
ABSTRACT:
The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and/or integrin receptors to produce increased sequestration of and/or accumulation of and/or uptake of Aβ, and/or changes in cathepsin D content and/or lysosomal dysfunction, and/or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and/or accumulation of and/or uptake of Aβ, and/or lysosomal dysfunction, and/or changes in cathepsin D content and/or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and/or accumulation.
REFERENCES:
patent: 4366241 (1982-12-01), Tom et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4517288 (1985-05-01), Giegel et al.
patent: 4837168 (1989-06-01), de Jaeger et al.
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5627059 (1997-05-01), Capecchi et al.
patent: 5767337 (1998-06-01), Roses et al.
patent: 5830678 (1998-11-01), Carter
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 6046381 (2000-04-01), Mucke et al.
patent: 6120991 (2000-09-01), Carter et al.
patent: 2002/0048746 (2002-04-01), Lynch et al.
patent: WO 92/00091 (1992-01-01), None
patent: WO 93/20242 (1993-10-01), None
Harris-White, M. E. et al. Effects of Transforming Growth Factor-Beta (Isoforms 1-3) on Amyloid-Beta Depostion, Inflammation and Cell Targeting in Organotypic Hippocampal Slice Cultures. The Journal of Neuroscience. Dec. 1998, vol. 18, pp. 10366-10374.
Matter et al. The Alpha5Beta1 Integrin Mediates Elimination of Amyloid-Beta Peptide and Protects Against Apoptosis. Journal of Cell Biology. May 18, 1998, vol. 141, pp. 1019-1030.
Hab et al. Physical Interaction of ApoE with Amyloid Precursor Protein Independent of the Amyloid A-Beta Region In Vitro Journal of Biolog. Chem. May 29, 1998, vol. 273, pp. 13892-13897.
Sćarborough et al, Journal of Biological Chemistry, 266:9359-9362, 1991.
Hass et al, Journal of Biological Chemistry, 273:13892-13897, 1998.
Akiyama, H., et al., “Inflammation and Alzheimer's disease,”Neurobiol. Aging 21:383-421, Elsevier Science (May-Jun. 2000).
Backstrom, J.R., et al., “Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1-40),”J. Neurosci. 16:7910-7919, Society for Neuroscience (1996).
Bahr, B.A., et al., “Stable Maintenance of Glutamate Receptors and Other Synaptic Components in Long-Term Hippocampal Slices,”Hippocampus5:425-439, Wiley-Liss (1995).
Bahr, B.A., et al., “Amyloid β Protein is Internalized Selectively by Hippocampal Field CA1 and Causes Neurons to Accumulate Amyloidogenic Carboxyterminal Fragments of the Amyloid Precursor Protein,”J. Comp. Neurol. 397:139-147, Wiley-Liss (1998).
Bahr, B., and Lynch, G., “Purification of an Arg-Gly-Asp selective matrix receptor from brain synaptic plasma membranes,”Biochem. J. 281:137-142, The Biochemical Society/Portland Press (1992).
Bahr, B.A., et al., “Fibronectin binding by brain synaptosomal membranes may not involve conventional integrins,”Neuroreport 2:13-16, Rapid Communications of Oxford (1991).
Bahr, B.A., et al., “Arg-Gly-Asp-Ser-Selective Adhesion and the Stabilization of Long-Term Potentiation: Pharmacological Studies and the Characterization of a Candidate Matrix Receptor,”J. Neurosci. 17:1320-1329, Society for Neuroscience (1997).
Bahr, B.A., “Integrin-Type Signaling Has a Distinct Influence on NMDA-Induced Cytoskeletal Disassembly,”J. Neurosci. Res. 59:827-832, Wiley-Liss (Mar. 2000).
Bard, F., et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med. 6:916-919, Nature America Inc. (Aug. 2000).
Barrett, A.J., and Kirschke, H., “Cathepsin B, Cathepsin H, and Cathepsin L,”Meth. Enzymol. 80:535-561, Academic Press (1981).
Beattie, E.C., et al., “Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD,”Nat. Neurosci. 3:1291-1300, Nature America Inc. (Dec. 2000).
Bednarski, E., and Lynch, G., “Cytosolic Proteolysis of τ by Cathepsin D in Hippocampus Following Suppression of Cathepsins B and L,”J. Neurochem. 67:1846-1855, Lippincott-Raven Publishers (1996).
Bednarski, E., and Lynch, G., “Selective suppression of cathepsin L results from elevations in lysosomal pH and is followed by proteolysis of tau protein,”NeuroReport 9:2089-2094, Rapid Science (1998).
Bi, X., et al., “Polarized Distribution of α5 Integrin in Dendrites of Hippocampal and Cortical Neurons,”J. Comp. Neurol. 435:184-193, Wiley-Liss (Jun. 2001).
Bi, X., et al., “Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus,”J. Neurochem. 74:1469-1477, Lippincott Williams & Wilkins (Apr. 2000).
Brion, J.-P., et al., “Neurofilament Monoclonal Antibodies RT97 and 8D8 Recognize Different Modified Epitopes in Paired Helical Filament-τ in Alzheimer's Disease,”J. Neurochem. 60:1372-1382, Raven Press (1993).
Bruce, A.J., et al., “β-Amyloid toxicity in organotypic hippocampal cultures: Protection by EUK-8, a synthetic catalytic free radical scavenger,”Proc. Natl. Acad. Sci. USA 93:2312-2316, National Academy of Sciences (1996).
Burkin, D.J., et al., “A Functional Role for Specific Spliced Variants of the α7β1 Integrin in Acetylcholine Receptor Clustering,”J. Cell Biol. 143:1067-1075, The Rockefeller University Press (1998).
Burnashev, N., et al., “Control of Asparagine Residues of Calcium Permeability and Magnesium Blockade in the NMDA Receptor,”Science 257:1415-1419, American Association for the Advancement of Science (1992).
Busciglio, J., et al., “Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells,”Proc. Natl. Acad. Sci. USA 90:2092-2096, National Academy of Sciences (1993).
Callahan, L.M., et al., “Quantitative Decrease in Synaptophysin Message Expression and Increase in Cathepsin D Message Expression in Alzheimer Disease Neurons Containing Neurofibrillary Tangles,”J. Neuropathol. Exp. Neurol. 58:275-287, American Association of Neuropathologists (Mar. 1999).
Carroll, R.C., et al., “Dynamin-dependent endocytosis of ionotropic glutamate receptors,”Proc. Natl. Acad. Sci. USA 96:14112-14117, National Academy of Sciences (Nov. 1999).
Caswell, M.D., et al., “The amyloid β-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons,”Eur. J. Biochem. 266:509-516, Blackwell Science (Dec. 1999).
Cataldo, A.M., et al., “Gene Expression and Cellular Content of Cathepsin D in Alzheimer's Disease Brain: Evidence for Early Up-Regulation of the Endosomal-Lysosomal System,”Neuron 14:671-680, Cell Press (1995).
Chavis, P., and Westbrook, G., “Integrins mediate functional pre- and postsynaptic maturation at a hippocampal synapse,”Nature 411:317-321, Nature Publishing Group (May 2001).
Chazot, P.L., “CP-101606,”Curr. Opin. Investig. Drugs 1:370-374, PharmaPress (Nov. 2000).
Chen, C., et al., “‘Analogous’ Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis
Bi Xiaoning
Gall Christine M.
Lynch Gary
Crouch Deborah
Sterne Kessler Goldstein & Fox P.L.L.C.
The Regents of the University of California
LandOfFree
Determining the effect of a substance on sequestration,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determining the effect of a substance on sequestration,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining the effect of a substance on sequestration,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727142